Despite many studies of the likely survival outcome of individual patients with colorectal
cancer, our knowledge of this subject remains poor. Until recently, we had virtually no …

Diarrhea is one of the main drawbacks for cancer patients. Possible etiologies could be
radiotherapy, chemotherapeutic agents, decreased physical performance, graft versus host …

PURPOSE Differentiating the irinotecan dose on the basis of the uridine diphosphate
glucuronosyltransferase 1A1 (UGT1A1) genotype improves the pathologic complete …

Despite initial enthusiasm, 1, 2, 3 the use of pharmacogenetics has remained limited to
investigation in only a few clinical fields such as oncology and psychiatry. 4, 5, 6, 7, 8 The …

A meta-analysis in Caucasians was conducted to investigate the possible association of
uridine diphosphate glucuronosyltransferase (UGT) 1A1 gene polymorphisms with …

During the past two decades the first sequencing of the human genome was performed
showing its high degree of inter-individual differentiation, as a result of large international …

The anticancer drug irinotecan shows serious dose-limiting gastrointestinal toxicity
regardless of intravenous dosing. Although enzymes and transporters involved in irinotecan …

Abstract Background Pre-therapeutic UGT1A1 genotyping is not yet routinely performed in
most hospitals in patients starting irinotecan chemotherapy. The aim of this position paper …

Abstract Irinotecan and 5-fluorouracil (5-FU) are used to treat metastatic colorectal cancer.
Irinotecan's active metabolite is inactivated by UDP-glucuronosyltransferase 1A1 (UGT1A1) …

Irinotecan is a major drug in the treatment of advanced colorectal cancer. Its active form is
the SN 38 metabolite, which is cleared by the biliary route after glucuronidation by uridine …